Bio-Rad Laboratories (Bio-Rad Laboratories) Gross Margin %

: 53.78% (As of Dec. 2023)

View and export this data going back to 1980. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Bio-Rad Laboratories's Gross Profit for the three months ended in Dec. 2023 was $366 Mil. Bio-Rad Laboratories's Revenue for the three months ended in Dec. 2023 was $681 Mil. Therefore, Bio-Rad Laboratories's Gross Margin % for the quarter that ended in Dec. 2023 was 53.78%.

The historical rank and industry rank for Bio-Rad Laboratories's Gross Margin % or its related term are showing as below:

BIO' s Gross Margin % Range Over the Past 10 Years
Min: 53.42 Med: 55.02 Max: 56.48
Current: 53.42

During the past 13 years, the highest Gross Margin % of Bio-Rad Laboratories was 56.48%. The lowest was 53.42%. And the median was 55.02%.

BIO's Gross Margin % is ranked worse than
50.25% of 796 companies
in the Medical Devices & Instruments industry
Industry Median: 53.54 vs BIO: 53.42

Bio-Rad Laboratories had a gross margin of 53.78% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Bio-Rad Laboratories was 0.20% per year.

Bio-Rad Laboratories Gross Margin % Historical Data

The historical data trend for Bio-Rad Laboratories's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

54.38

56.48

56.05

55.93

53.42

Bio-Rad Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															54.38	53.55	53.22	53.10	53.78

Competitive Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories Gross Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Gross Margin % falls into.

Bio-Rad Laboratories Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Bio-Rad Laboratories's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1426.9	/	2671.262
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(2671.262 - 1244.316)	/	2671.262
	=	53.42 %

Bio-Rad Laboratories's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	366.4	/	681.184
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(681.184 - 314.821)	/	681.184
	=	53.78 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Bio-Rad Laboratories (NYSE:BIO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Bio-Rad Laboratories had a gross margin of 53.78% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Bio-Rad Laboratories Gross Margin % Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

BIO.B:USA BUW:Germany BUWA:Germany

Address

1000 Alfred Nobel Drive, Hercules, CA, USA, 94547

Website

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Executives

Tania Devilliers	officer: INT PRIN ACCTG OFC	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Sedat Evran	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Corey Colleen	officer: EVP, Global Human Resources	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Diane Dahowski	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Schwartz Allison	director	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Simon May	officer: EVP, President, LSG	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew J. Last	officer: EVP, Chief Operating Officer	3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Ajit Ramalingam	officer: SVP, Chief Accounting Officer	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Ilan Daskal	officer: EVP, Chief Financial Officer	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Timothy S Ernst	officer: EVP, General Counsel & Sec	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Dara Wright	officer: Executive Vice President	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Michael Crowley	officer: EVP, GBL Commercial Operations	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Steven D Schwartz	10 percent owner	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice N Schwartz	director, 10 percent owner
Norman D Schwartz	director, 10 percent owner, officer: Chairman, President, and CEO	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547